Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 May, 2018 04:54 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Sun Pharmaceutical Industries quarterly earnings up 7% - 25-May-2018 16:12
Tech Mahindra quarterly profit zooms 2.09 times to Rs 12.31 bn - 25-May-2018 16:02
Treatment of home buyers as financial creditors could impact real estate sector: Ind-Ra - 25-May-2018 15:21
Lupin submits MAA for Etanercept Biosimilar in Europe - 25-May-2018 12:35
HDFC Sec maintains 'Buy' on Granules India - 25-May-2018 11:37
Zydus Cadila gets USFDA nod for Dutasteride, Tamsulosin HCl capsules - 25-May-2018 11:05
Pidilite Industries quarterly earnings surge 57.43% - 25-May-2018 10:34
United Breweries quarterly earnings soar 13.51 times - 25-May-2018 10:23
PNC Infra emerges lowest bidder for Purvanchal Expressway project - 25-May-2018 10:07
MEP Infrastructure Developers receives LoA from NHAI - 25-May-2018 10:02
Larsen & Tubro bags order worth Rs 31.91 bn - 25-May-2018 09:57
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer